TY - JOUR
T1 - Management of Stage III Non-Small-Cell Lung Cancer
T2 - ASCO Guideline
AU - Daly, Megan E.
AU - Singh, Navneet
AU - Ismaila, Nofisat
AU - Antonoff, Mara B.
AU - Arenberg, Douglas A.
AU - Bradley, Jeffrey
AU - David, Elizabeth
AU - Detterbeck, Frank
AU - Früh, Martin
AU - Gubens, Matthew A.
AU - Moore, Amy C.
AU - Padda, Sukhmani K.
AU - Patel, Jyoti D.
AU - Phillips, Tanyanika
AU - Qin, Angel
AU - Robinson, Clifford
AU - Simone, Charles B.
N1 - Publisher Copyright:
© 2022 American Society of Clinical Oncology.
PY - 2022/4/20
Y1 - 2022/4/20
N2 - PURPOSETo provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC).METHODSAn Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTSThe literature search identified 127 relevant studies to inform the evidence base for this guideline.RECOMMENDATIONSEvidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
AB - PURPOSETo provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC).METHODSAn Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTSThe literature search identified 127 relevant studies to inform the evidence base for this guideline.RECOMMENDATIONSEvidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at www.asco.org/thoracic-cancer-guidelines.
KW - Carcinoma, Non-Small-Cell Lung/therapy
KW - Humans
KW - Lung Neoplasms/therapy
KW - Medical Oncology/methods
KW - Quality of Life
KW - Radiation Oncology
UR - http://www.scopus.com/inward/record.url?scp=85128493506&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000799692000011&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1200/JCO.21.02528
DO - 10.1200/JCO.21.02528
M3 - Article
C2 - 34936470
SN - 0732-183X
VL - 40
SP - 1356
EP - 1384
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -
